# LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer

> **NCT04560972** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 3 (actual)

## Conditions studied

- Extensive Stage Lung Small Cell Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Protein Phosphatase 2A Inhibitor LB-100

## Key facts

- **NCT ID:** NCT04560972
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-28
- **Primary completion:** 2027-01-27
- **Final completion:** 2027-01-27
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04560972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04560972, "LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04560972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*